Equities

Integra Lifesciences Holdings Corp

Integra Lifesciences Holdings Corp

Actions
  • Price (EUR)23.60
  • Today's Change-1.20 / -4.84%
  • Shares traded59.00
  • 1 Year change-33.33%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:06 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments309457513
Total Receivables, Net259274243
Total Inventory390325317
Prepaid expenses6710780
Other current assets, total33--0
Total current assets1,0581,1611,154
Property, plant & equipment, net496460396
Goodwill, net1,0551,0391,013
Intangibles, net1,0681,1271,146
Long term investments------
Note receivable - long term------
Other long term assets585716
Total assets3,7823,8903,782
LIABILITIES
Accounts payable9210262
Accrued expenses192173228
Notes payable/short-term debt000
Current portion long-term debt/capital leases153845
Other current liabilities, total8.547.255.30
Total current liabilities307321340
Total long term debt1,4851,4051,501
Total debt1,5001,4431,546
Deferred income tax356346
Minority interest------
Other liabilities, total367296211
Total liabilities2,1942,0852,098
SHAREHOLDERS EQUITY
Common stock0.910.910.90
Additional paid-in capital1,3021,2771,265
Retained earnings (accumulated deficit)947879699
Treasury stock - common(647)(363)(234)
Unrealized gain (loss)------
Other equity, total(15)10(45)
Total equity1,5881,8041,685
Total liabilities & shareholders' equity3,7823,8903,782
Total common shares outstanding788485
Treasury shares - common primary issue136.824.90
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.